{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:08Z","timestamp":1790805128606,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["67985904"],"award-info":[{"award-number":["67985904"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["2012-305121"],"award-info":[{"award-number":["2012-305121"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["LO1609"],"award-info":[{"award-number":["LO1609"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.omtm.2019.10.008","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:42:15Z","timestamp":1572266535000},"page":"343-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Raygene","family":"Martier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sogorb-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Stricker-Shaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"H\u00fcbener-Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonay","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Klima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewijk J.","family":"Toonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Juhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Juhasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Ellederova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Motlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huu Phuc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.10.008_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jnc.14541","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy","volume":"148","author":"Matos","year":"2019","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtm.2019.10.008_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1212\/WNL.28.7.703","article-title":"Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions","volume":"28","author":"Coutinho","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2019.10.008_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870070302","article-title":"Machado-Joseph disease: an autosomal dominant motor system degeneration","volume":"7","author":"Rosenberg","year":"1992","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtm.2019.10.008_bib4","first-page":"603","article-title":"Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia","volume":"57","author":"Ranum","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(04)00737-9","article-title":"Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis","volume":"3","author":"Sch\u00f6ls","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2019.10.008_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng1194-221","article-title":"CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1","volume":"8","author":"Kawaguchi","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib7","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/archneur.58.11.1821","article-title":"Improvement in the molecular diagnosis of Machado-Joseph disease","volume":"58","author":"Maciel","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omtm.2019.10.008_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev.genom.1.1.281","article-title":"Trinucleotide repeats: mechanisms and pathophysiology","volume":"1","author":"Cummings","year":"2000","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib9","first-page":"54","article-title":"Correlation between CAG repeat length and clinical features in Machado-Joseph disease","volume":"57","author":"Maciel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-6-35","article-title":"Machado-Joseph disease: from first descriptions to new perspectives","volume":"6","author":"Bettencourt","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2019.10.008_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0168-0102(97)00056-4","article-title":"Machado-Joseph disease gene products carrying different carboxyl termini","volume":"28","author":"Goto","year":"1997","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s100380170060","article-title":"The genomic structure and expression of MJD, the Machado-Joseph disease gene","volume":"46","author":"Ichikawa","year":"2001","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0896-6273(00)80943-5","article-title":"Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3","volume":"19","author":"Paulson","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2019.10.008_bib14","doi-asserted-by":"crossref","first-page":"e5834","DOI":"10.1371\/journal.pone.0005834","article-title":"Nucleocytoplasmic shuttling activity of ataxin-3","volume":"4","author":"Macedo-Ribeiro","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.10.008_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1750-3639.1998.tb00193.x","article-title":"An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients","volume":"8","author":"Schmidt","year":"1998","journal-title":"Brain Pathol."},{"key":"10.1016\/j.omtm.2019.10.008_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/nbdi.1998.0208","article-title":"Heterogeneous intracellular localization and expression of ataxin-3","volume":"5","author":"Trottier","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2019.10.008_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","article-title":"SCA3: neurological features, pathogenesis and animal models","volume":"7","author":"Riess","year":"2008","journal-title":"Cerebellum"},{"key":"10.1016\/j.omtm.2019.10.008_bib18","first-page":"1513","article-title":"Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies","volume":"49","author":"Evers","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omtm.2019.10.008_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00018-010-0522-4","article-title":"Muscleblind participates in RNA toxicity of expanded CAG and CUG repeats in Caenorhabditis elegans","volume":"68","author":"Wang","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtm.2019.10.008_bib20","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","article-title":"Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy","volume":"19","author":"Miller","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.omtm.2019.10.008_bib21","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/nar\/29.13.2766","article-title":"In\u00a0vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts","volume":"29","author":"Fardaei","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib22","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3174\/ajnr.A2387","article-title":"Quantitative assessment of brain stem and cerebellar atrophy in spinocerebellar ataxia types 3 and 6: impact on clinical status","volume":"32","author":"Eichler","year":"2011","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.omtm.2019.10.008_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mds.870070303","article-title":"Machado-Joseph disease in New England: clinical description and distinction from the olivopontocerebellar atrophies","volume":"7","author":"Sudarsky","year":"1992","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtm.2019.10.008_bib25","first-page":"139","article-title":"Epidemiology and clinical aspects of Machado-Joseph disease","volume":"61","author":"Sequeiros","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.omtm.2019.10.008_bib26","doi-asserted-by":"crossref","first-page":"e52396","DOI":"10.1371\/journal.pone.0052396","article-title":"Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice","volume":"8","author":"N\u00f3brega","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.10.008_bib27","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","article-title":"Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?","volume":"19","author":"Alves","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/mt.2013.152","article-title":"Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice","volume":"21","author":"Rodr\u00edguez-Lebr\u00f3n","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib29","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s Disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib30","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.10.008_bib31","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of microRNA-based huntingtin-lowering therapies from preclinical studies to the clinic","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib32","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1093\/nar\/gkx779","article-title":"Dicer-independent processing of small RNA duplexes: mechanistic insights and applications","volume":"45","author":"Herrera-Carrillo","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","article-title":"AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes","volume":"15","author":"Keskin","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.10.008_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1006\/exnr.2002.7942","article-title":"Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain","volume":"176","author":"Klein","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtm.2019.10.008_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","article-title":"Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy","volume":"16","author":"Martier","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.10.008_bib36","doi-asserted-by":"crossref","first-page":"15163","DOI":"10.1073\/pnas.1006432107","article-title":"Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.10.008_bib37","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1126\/science.1190809","article-title":"A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity","volume":"328","author":"Cifuentes","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.10.008_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nature09092","article-title":"A Dicer-independent miRNA biogenesis pathway that requires Ago catalysis","volume":"465","author":"Cheloufi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.10.008_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.celrep.2013.09.029","article-title":"Poly(A)-specific ribonuclease mediates 3\u2032-end trimming of Argonaute2-cleaved precursor microRNAs","volume":"5","author":"Yoda","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2019.10.008_bib40","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1358\/dof.2009.34.12.1443434","article-title":"Therapeutic prospects for spinocerebellar ataxia type 2 and 3","volume":"34","author":"Bezprozvanny","year":"2009","journal-title":"Drugs Future"},{"key":"10.1016\/j.omtm.2019.10.008_bib41","doi-asserted-by":"crossref","first-page":"e62043","DOI":"10.1371\/journal.pone.0062043","article-title":"Cerebellar soluble mutant ataxin-3 level decreases during disease progression in spinocerebellar ataxia type 3 mice","volume":"8","author":"Nguyen","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.10.008_bib42","doi-asserted-by":"crossref","first-page":"e1005460","DOI":"10.1371\/journal.pcbi.1005460","article-title":"Highly accessible AU-rich regions in 3\u2032 untranslated regions are hotspots for binding of regulatory factors","volume":"13","author":"Plass","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.omtm.2019.10.008_bib43","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/nar\/gks797","article-title":"siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse","volume":"41","author":"Boudreau","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2007.08.062","article-title":"Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination","volume":"362","author":"Schmitt","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtm.2019.10.008_bib45","doi-asserted-by":"crossref","first-page":"e3341","DOI":"10.1371\/journal.pone.0003341","article-title":"Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease","volume":"3","author":"Alves","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.10.008_bib46","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.10.008_bib47","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2019.10.008_bib48","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1093\/nar\/gkt693","article-title":"ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib49","doi-asserted-by":"crossref","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.10.008_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.omtn.2019.01.010","article-title":"Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients","volume":"14","author":"Martier","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.10.008_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.10.008_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtm.2019.10.008_bib53","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-associated virus-based gene therapy for CNS diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib54","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2019.10.008_bib56","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.10.008_bib57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","article-title":"Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice","volume":"8","author":"Toonen","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.10.008_bib59","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/mt.2013.144","article-title":"Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease","volume":"21","author":"Costa","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.10.008_bib60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ijnp\/pyx092","article-title":"Studies on prostaglandin-endoperoxide synthase 1: lower levels in schizophrenia and after treatment with antipsychotic drugs in conjunction with aspirin","volume":"21","author":"Dean","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.omtm.2019.10.008_bib61","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.yexcr.2005.12.035","article-title":"Formin-1 protein associates with microtubules through a peptide domain encoded by exon-2","volume":"312","author":"Zhou","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib62","doi-asserted-by":"crossref","first-page":"e1006660","DOI":"10.1371\/journal.pgen.1006660","article-title":"TDRD6 mediates early steps of spliceosome maturation in primary spermatocytes","volume":"13","author":"Akp\u0131nar","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtm.2019.10.008_bib63","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.3390\/ijms18010062","article-title":"Lysyl oxidase and the tumor microenvironment","volume":"18","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2019.10.008_bib64","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nature04695","article-title":"Lysyl oxidase is essential for hypoxia-induced metastasis","volume":"440","author":"Erler","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.10.008_bib65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/0008-5472.CAN-15-2306","article-title":"Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis","volume":"76","author":"Cox","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib66","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1158\/0008-5472.CAN-04-1543","article-title":"Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers","volume":"64","author":"Kaneda","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.10.008_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molonc.2015.07.005","article-title":"Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide","volume":"10","author":"Ozdener","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omtm.2019.10.008_bib68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12311-011-0340-8","article-title":"Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3)","volume":"11","author":"Scherzed","year":"2012","journal-title":"Cerebellum"},{"key":"10.1016\/j.omtm.2019.10.008_bib69","first-page":"17","article-title":"Machado-Joseph disease","volume":"3","author":"Sudarsky","year":"1995","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.omtm.2019.10.008_bib70","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410390411","article-title":"Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features","volume":"39","author":"D\u00fcrr","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2019.10.008_bib71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00401-007-0287-5","article-title":"CAG repeat disorder models and human neuropathology: similarities and differences","volume":"115","author":"Yamada","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtm.2019.10.008_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00110-7","article-title":"Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease","volume":"200","author":"Mu\u00f1oz","year":"2002","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.omtm.2019.10.008_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WCO.0b013e3282f7673d","article-title":"New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease)","volume":"21","author":"R\u00fcb","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omtm.2019.10.008_bib74","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ana.410410408","article-title":"Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain","volume":"41","author":"Paulson","year":"1997","journal-title":"Ann. Neurol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:25:44Z","timestamp":1762421144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119301160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":74,"alternative-id":["S2329050119301160"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.10.008","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}